Phenelzine

GPTKB entity

Statements (53)
Predicate Object
gptkbp:instance_of gptkb:depression
gptkbp:administered_by oral tablet
gptkbp:approves gptkb:1959
gptkb:FDA
gptkbp:available_on generic drug
gptkbp:brand Nardil
gptkbp:casnumber 51-71-8
gptkbp:chemical_formula C12 H12 N2 O3
gptkbp:class gptkb:depression
hydrazine derivative
gptkbp:clinical_trial depression treatment
anxiety treatment
gptkbp:composed_by reduction of phenylhydrazine
gptkbp:contraindication gptkb:pheochromocytoma
liver disease
heart disease
history of stroke
gptkbp:developed_by gptkb:Parke-Davis
gptkbp:discovery_year 1950s
gptkbp:dosage_form 15 to 90 mg per day
https://www.w3.org/2000/01/rdf-schema#label Phenelzine
gptkbp:interacts_with tyramine
opioids
stimulants
certain antidepressants
gptkbp:lifespan 11 to 16 hours
gptkbp:marketed_as gptkb:Australia
gptkb:Canada
gptkb:United_Kingdom
gptkb:United_States
gptkbp:mechanism_of_action inhibits monoamine oxidase
gptkbp:metabolism liver
gptkbp:related_to mental health treatment
MAO inhibitors
psychotropic drugs
antidepressant medications
neurotransmitter modulation
gptkbp:requires prescription only
gptkbp:side_effect dizziness
nausea
seizures
insomnia
dry mouth
weight gain
hypertensive crisis
sexual dysfunction
peripheral edema
serotonin syndrome
gptkbp:used_for gptkb:depression
anxiety disorders
gptkbp:bfsParent gptkb:Sunovion_Pharmaceuticals
gptkb:Monoamine_oxidase_inhibitors
gptkbp:bfsLayer 7